Given that atazanavir (ATV) increases bilirubin in an exposure-dependent manner, we tested whether bilirubin levels could be used as a surrogate of virological response to ATV-based regimens in 182 patients. Bilirubin increases of ≥0.7 mg/dl were independently associated with early virological response with an odds ratio of 5.2 (95% confidence interval 2.2–11.9). Total bilirubin, a nonexpensive, simple, and widely available parameter, might be used as a surrogate of virological response to ATV-based regimens, especially in areas with limited resources where HIV-RNA testing is not available.
Get full access to this article
View all access options for this article.
References
1.
RivasP, MorelloJ, GarridoC, Rodriguez-NovoaS, SorianoV. Role of atazanavir in the treatment of HIV infection. Ther Clin Risk Manag, 2009; 5:99–116.
2.
ZhangD, ChandoTJ, EverettDW, PattenCJ, DehalSS, HumphreysWG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos, 2005; 33:1729–1739.
3.
Rodriguez-NovoaS, Martin-CarboneroL, BarreiroPet al.Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS, 2007; 21:41–46.
4.
Rodriguez NovoaS, BarreiroP, RendonAet al.Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C→T polymorphism at the multidrug resistance gene 1. Clin Infect Dis, 2006; 42:291–295.
5.
La PorteCJL, BackDJ, BlaschkeT, BoucherCAB, FletcherCV, FlexnerJG. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev Antiviral Ther, 2008; 3:3–14.
6.
Division of AIDS Table for Grading the severity of adult and pediatric adverse events Version 1.0, December 2004; clarification August 2009. http://rsc.tech-res.com/safetyandpharmacovigilance/.
7.
HungCH, LeeCM, LuSNet al.Anemia associated with antiviral therapy in chronic hepatitis C: Incidence, risk factors, and impact on treatment response. Liver Int, 2006; 26:1079–1086.
8.
LindahlK, StahleL, BruchfeldA, SchvarczR. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology, 2005; 41:275–279.
9.
PetersenK, RiddleMS, JonesLEet al.Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy. AIDS, 2005; 19:1700–1702.
